Raptor, TorreyPines deal

The companies will merge in a stock deal. Raptor shareholders will own 95% of the combined company and TorreyPines shareholders will own 5%. The combined company will retain Raptor's name, management and headquarters and expects to trade on NASDAQ. It will focus on developing Raptor's pipeline, which includes DR Cysteamine. The delayed-release formulation of a degradation product of the amino acid cysteine is in Phase IIb testing for nephropathic cystinosis, and Phase IIa testing for non-alcoholic steatohepatitis (NASH). ...